RxDoctor Payments Data

Mark Pippenger, MD

Neurology · North Little Rock, ARNPI 1235248246

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $98,910 of the $109,274 with a category attached, or 90.5%. Lilly USA, LLC accounts for 67.1% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $57,249, more than ten times the $172 reported in 2019. Among neurology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$109,274in general payments, 2019–2025

Across 168 payments — averaging $650.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$73K
  • Eisai Inc.$35K
  • Biogen$535
  • Acadia Pharmaceuticals Inc$172
  • Life Molecular Imaging Ltd$125
  • Neurocrine Biosciences, Inc.$41
  • plus $161 from 8 others

What the payments were for

  • Consulting fees$3,2753%
  • Speaking & faculty fees$98,91091%
  • Travel & lodging$3,4173%
  • Food & beverage$3,6283%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,274 in reported general payments places this provider in the 95th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$110,729
Medicare patients
380
Services billed
1,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$116,757
Donepezil Hcl490$5,284
Galantamine Hbr19$1,324
Levetiracetam14$250
Sertraline Hcl54$236
Gabapentin18$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$41$116,75714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 neurology providers in Arkansas.

Other neurology in North Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →